These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 10316828)
1. Understanding the FDA's guarded system for classifying new drugs. Schneiweiss F Hosp Pharm; 1979 May; 14(5):262-4, 266, 268 passim. PubMed ID: 10316828 [No Abstract] [Full Text] [Related]
2. The FDA's classification system for new drugs. An evaluation of therapeutic gain. Finkel MJ N Engl J Med; 1980 Jan; 302(3):181-3. PubMed ID: 7350458 [No Abstract] [Full Text] [Related]
3. FDA's classification of new drugs. Schneiweiss F N Engl J Med; 1980 Jun; 302(24):1368-9. PubMed ID: 7374693 [No Abstract] [Full Text] [Related]
4. The FDA's new drug rating system. Ohio Med; 1991 Mar; 87(3):133-4. PubMed ID: 2030884 [No Abstract] [Full Text] [Related]
7. FDA-USP drug product problem reporting program--an update. Wheatley LS Hosp Formul; 1979 Mar; 14(3):359-60, 365. PubMed ID: 10316797 [No Abstract] [Full Text] [Related]
8. The FDA's response to AIDS: paradigm shift in new drug policy? Podraza R Food Drug Law J; 1993; 48(3):351-75. PubMed ID: 11653267 [No Abstract] [Full Text] [Related]
9. Classification and coding considerations for drug data base design. Forbes MB J Clin Comput; 1983; 12(3):88-100. PubMed ID: 10317426 [No Abstract] [Full Text] [Related]
10. Linking a policy on nonformulary drugs to the FDA's therapeutic-potential classification system. Poirier TI; Vorbach M; Bache T Am J Hosp Pharm; 1994 Sep; 51(18):2277-8. PubMed ID: 7801989 [No Abstract] [Full Text] [Related]
11. FDA's Rx for better medication information. Farley D FDA Consum; 1995 Nov; 29(9):5-10. PubMed ID: 10152787 [TBL] [Abstract][Full Text] [Related]
12. FDA's perspective on women and drugs. Danello MA NIDA Res Monogr; 1986; 65():9-13. PubMed ID: 3090447 [No Abstract] [Full Text] [Related]
14. Implications of FDA's proposal to include foreign marketing experience in the over-the-counter drug review process. Pinco RG Food Drug Law J; 1998; 53(1):105-22. PubMed ID: 11795327 [No Abstract] [Full Text] [Related]
15. Upon closer inspection. As the U.S. imports more drugs and devices, the FDA's overseas initiatives aim to head off trouble at the source. Rhea S Mod Healthc; 2009 Mar; 39(13):28-30. PubMed ID: 19405431 [No Abstract] [Full Text] [Related]
16. Impact of FDA's new drug rule? Not much. Holthaus D Hospitals; 1987 Aug; 61(15):106. PubMed ID: 3596532 [No Abstract] [Full Text] [Related]
17. PDA's response to FDA's "Guideline on sterile drug products produced by aseptic processing". Akers JE; Agalloco JP; Carleton FJ; Korczynski MS J Parenter Sci Technol; 1988; 42(4):114-7. PubMed ID: 3183865 [No Abstract] [Full Text] [Related]
18. Public affairs specialists: on the FDA's front line. Bren L FDA Consum; 2002; 36(6):31-5. PubMed ID: 12523299 [No Abstract] [Full Text] [Related]
19. When is a medical product too risky? An interview with FDA's top drug official. Interview by Tamar Nordenberg. Woodcock J FDA Consum; 1999; 33(5):8-11, 13. PubMed ID: 10522164 [No Abstract] [Full Text] [Related]
20. FDA's efforts to improve access to agency records. Shroff AP; Sheehan SM Food Drug Law J; 1998; 53(2):321-6. PubMed ID: 10346687 [No Abstract] [Full Text] [Related] [Next] [New Search]